Mifamurtide

{
  "id": "MLC-T-ONC-005378",
  "term": "Mifamurtide",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug being studied in the treatment of young adults with bone cancer that has gotten worse or come back. Mifamurtide activates certain types of white blood cells and helps the immune system kill cancer cells. It is a type of immunostimulant. Also called L-MTP-PE, MEPACT, and muramyl tripeptide phosphatidylethanolamine.",
    "A liposomal formulation containing a muramyl dipeptide (MDP) analogue with potential immunomodulatory and antineoplastic activities.. Muramyl tripeptide phosphatidylethanolamine (MTP-PE), a derivative of the mycobacterial cell wall component MDP, activates both monocytes and macrophages. Activated macrophages secrete cytokines and induce the recruitment and activation of other immune cells, which may result in indirect tumoricidal effects. Liposomal encapsulation of MTP-PE prolongs its half-life and enhances tissue targeting."
  ],
  "abbreviation": "L-MTP-PE",
  "synonyms": [
    "L-MTP-PE",
    "MEPACT",
    "muramyl tripeptide phosphatidylethanolamine",
    "muramyl tripeptide phosphatidylethanolamine liposome",
    "CGP 19835A Lipid"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/mifamurtide/"
}